Theriva Biologics Inc (TOVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,478 | -19,685 | -13,240 | -8,750 | -4,273 |
| Depreciation Amortization | 32 | 85 | 60 | 36 | 18 |
| Income taxes - deferred | -330 | -1,425 | -867 | -532 | N/A |
| Accounts payable and accrued liabilities | -440 | -385 | -504 | -295 | 13 |
| Other Working Capital | -1,177 | -806 | 94 | 115 | -804 |
| Other Operating Activity | 783 | 3,134 | 743 | 168 | 144 |
| Operating Cash Flow | $-5,610 | $-19,082 | $-13,714 | $-9,258 | $-4,902 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -8 | -116 | -25 | -14 | N/A |
| Net Acquisitions | N/A | -3,863 | -3,863 | -3,863 | -3,863 |
| Other Investing Activity | 0 | -417 | -417 | -417 | -417 |
| Investing Cash Flow | $-8 | $-4,396 | $-4,305 | $-4,294 | $-4,280 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -55 | -1,376 | -1,376 | -1,376 | -1,376 |
| Common Stock Repurchased | N/A | -288 | N/A | N/A | N/A |
| Other Financing Activity | 0 | -266 | 2,734 | 0 | 0 |
| Financing Cash Flow | $-55 | $-1,930 | $1,358 | $-1,376 | $-1,376 |
| Exchange Rate Effect | -35 | -32 | -84 | -35 | 28 |
| Beginning Cash Position | 41,884 | 67,325 | 67,325 | 67,325 | 67,325 |
| End Cash Position | 36,176 | 41,885 | 50,580 | 52,362 | 56,795 |
| Net Cash Flow | $-5,708 | $-25,408 | $-16,745 | $-14,963 | $-10,530 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,610 | -19,082 | -13,714 | -9,258 | -4,902 |
| Capital Expenditure | -8 | -116 | -25 | -14 | N/A |
| Free Cash Flow | -5,618 | -19,198 | -13,739 | -9,272 | -4,902 |